Actualización de las perspectivas para el año fiscal 24 y el año fiscal 25
16 de abril de 2024
Dr. Martens plc
FY24 in line with expectations and update on FY25 outlook
Resultados del AF24
Dr. Martens Plc (the Company) will announce its FY24 results on 30th May, with results expected to be in line with guidance and consensus expectations.
As expected, we saw a pick-up in Direct to Consumer ("DTC") in Q4, to high single-digit year-on-year growth, compared with a 3% decline in Q3 (all on constant currency terms). This was as a result of good growth across EMEA, a flat outcome in the USA and a very strong result in APAC, led by Japan. Q4 Group wholesale performed in line with our expectations.
FY25 planning assumptions
As we start the new financial year, the Board is taking a prudent view and would like to share with investors our planning assumptions:
· USA wholesale revenue is anticipated to be double-digit down year-on-year. We have recently finalised the Autumn/Winter order book, which makes up the majority of the second half of USA wholesale, and this is significantly down year-on-year. If wholesale customers become more optimistic, we could see in-season re-orders, however these are hard to predict. Given the nature of wholesale orders, the full benefit of any restock always has a lag into the following season. The decline in wholesale has a significant impact on profitability, with a base assumption being in the region of a £20m PBT impact year-on-year, assuming no meaningful in-season re-orders.
· We are seeing single-digit inflation in our cost base, and also intend to invest in retaining and incentivising talent throughout the organisation; together these equate to a year-on-year PBT headwind in the region of £35m. As previously communicated, we do not anticipate increasing prices further this year, and therefore in FY25 we are unable to offset cost inflation as we have in prior years.
· Given the ongoing challenging performance of our USA wholesale business, we expect to continue to require the additional inventory storage facilities in this market through FY25, and therefore the majority of the £15m of additional costs incurred in FY24 are expected to repeat in FY25.
· As previously communicated, we have a number of important investment projects underway, incurring operating costs in addition to capital expenditure, including our new Supply and Demand Planning system and Customer Data Platform. These projects are progressing well and will deliver benefits in outer years. We also continue to invest in brand marketing to drive future growth.
There is a wide range of potential outcomes for FY25 given that we have only recently started the year. However, we have assumed that revenue declines by single-digit percentage year-on-year and at the PBT level we could see a worst-case scenario of PBT of around one-third of the FY24 level. There are also scenarios where the profit outturn could be significantly better than this, with the key factor being if USA performance is stronger than our planning assumptions as we progress through the year. We will also look to drive cost savings wherever possible, whilst protecting our brand and future growth opportunities. Against this backdrop, we are focused on cash generation and have already significantly reduced purchases from the supply chain, which will underpin the strength of the balance sheet.
Our business is always second half weighted, however this year, given the phasing of USA wholesale and costs, this will particularly be the case.
Kenny Wilson, CEO, said, "The FY25 outlook is challenging, and the whole organisation is focused on our action plan to reignite boots demand, particularly in the USA, our largest market. The nature of USA wholesale is that when customers gain confidence in the market we will see a significant improvement in our business performance, but we are not assuming that this occurs in FY25.
"We have built an operating cost base in anticipation of a larger business, however with revenues weaker we are currently seeing significant deleverage through to earnings. Against this backdrop, we will be laser-focused on driving cost efficiencies where possible. We also have a number of ongoing investment projects which will deliver results in outer years. We continue to believe in our DTC-first strategy and the considerable headroom for growth. Our brand remains strong, and we have a compelling product pipeline. These all give us confidence as we look beyond this transition year into future years."
Consultas
Inversores y analistas
Bethany Barnes, directora de relaciones con inversores GME@dhr-rgv.com +44 7825 187465
Beth Callum, gerente de relaciones con inversionistas GME@dhr-rgv.com +44 203 995 2644
Prensa
H/Advisors Maitland +44 207 379 5151
Katharine Spence +44 7384 535739
Gill Hammond, Director of Communications +44 7384 214248
Sobre el Dr. Martens
Dr. Martens es una marca británica icónica fundada en 1960 en Northamptonshire. Producida originalmente para trabajadores que buscaban botas resistentes y duraderas, la marca fue rápidamente adoptada por diversas subculturas juveniles y movimientos musicales asociados. Desde entonces, Dr. Martens ha trascendido sus raíces de clase trabajadora sin dejar de celebrar su orgullosa herencia y, seis décadas después, personas de todo el mundo usan "Docs" o "DM's" como símbolo de empoderamiento y su propia actitud individual. . La Compañía es un componente del índice FTSE 250.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.